KGK Science begins Covid-related clinical trial

KGK Science launches virtual clinical trial to test the efficacy of a natural health product to ease symptoms of Covid-19

Photo: KGK Science president and CEO, Najla Guthrie (file photo)

THE FIRST ARM of a KGK Science clinical trial to test the efficacy of a natural health product to ease the symptoms of Covid-19 has launched in major cities across Ontario.

The accelerated phase 2 clinical trial, sponsored by Hofseth Biocare, will examine the efficacy of Cardio soft gels, a natural salmon oil-based reducer of eosinophil effector function, as a treatment for patients with Acute Respiratory Distress Syndrome (ARDS) caused by the SARS-CoV-2 virus, and will investigate the progression from mild to severe Covid-19 in infected patients who identify as former smokers and/or steroid-resistant asthma patients.

In this first arm of the trial, patients who are currently self-isolating with Covid-19 will participate in the study via a virtual platform, receiving online assessments and monitoring of study progression over a period of 28 days in their home. London-based KGK is actively recruiting participants in the Greater Toronto Area (GTA), Ottawa, Windsor-Essex County, Waterloo, Hamilton, Niagara Region, Middlesex-London, Guelph and Simcoe to take part in the natural health research study.

The second arm of the Health Canada approved randomized, comparator-controlled, open-label, parallel study will be conducted in Brazil and Mexico and will assess hospitalized patients receiving the best current antiviral standard of care (BSC). In addition to the efficacy of Cardio to assist in the alleviation of symptoms of Covid-19, the study will investigate patient’s daily oxygenation requirements and other outcomes including time to clinical recovery. This in-hospital arm is scheduled to begin by late November, pending regulatory approvals.

For more information on this clinical trial, click here.